The approach employed by the research team could be used against other diseases—including COVID-19 and influenza.

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Researchers at MIT and the Scripps Research Institute have shown that they can generate a strong immune response to HIV with ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving ...

For nearly 15 years, Dennis Burton worked on a project aimed at solving what he calls "one of the most difficult problems in ...

In the quest to develop an effective HIV vaccine, scientists from Scripps Research have made a significant leap forward. They ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT ...